Why can't a chart just tell me the answer?

Because the chart would have to know how much water you added, and it cannot. Milligrams are mass; units are volume. The bridge between them is concentration, and you set that yourself when you reconstituted the vial. Any page giving one fixed number is silently assuming a concentration on your behalf — and if that assumption is wrong by a factor of two, so is the dose.

Is this the same on a 0.3 mL, 0.5 mL and 1 mL syringe?

The volume is identical; how precisely you can measure it is not. All three are U-100 barrels, so 100 units is 1 mL on each and the unit figure is the same number on all of them. What differs is the printed scale: 0.3 mL and 0.5 mL barrels are graduated in 1-unit steps, a 1 mL barrel usually in 2-unit steps, and only the half-unit 0.3 mL barrel resolves 0.5 of a unit. For this dose that matters at 8 of the 10 concentrations below, where the answer is not a whole unit at all.

What if my syringe is U-40 instead of U-100?

Then every number on this page is wrong for it, and the error is invisible because the barrels look alike. U-40 is a veterinary scale, fixed at 40 units per mL by 21 CFR 522.1160 for animal insulin. The 25 unit mark that means 0.25 mL on a U-100 barrel means 0.625 mL on a U-40 one — two and a half times the volume, and two and a half times the dose. This is a documented, published cause of insulin dosing error in both directions, not a theoretical risk.

Is 2.5 mg the same as 2.5 mL?

No, and this is the single most expensive misreading of the question. Milligrams measure the drug; millilitres measure the liquid it is dissolved in. 2.5 mg occupies 0.751 mL at 2.5 mg/mL and 0.042 mL at 30 mg/mL — a 18-fold spread for the same stated dose. If a vendor tells you to "draw 2.5" without saying of what, the instruction is unusable.

How Many Units Is 2.5 mg of Tirzepatide?

Q: How Many Units Is 2.5 mg of Tirzepatide?

There is no single answer, and any page that gives one has quietly assumed a concentration on your behalf. A syringe unit measures volume — ISO 8537 fixes the U-100 scale so 100 units is 1 mL on every barrel — so 2.5 mg lands somewhere different in every vial. At 5 mg/mL it is 50 units, at 10 mg/mL it is 25 units, and at 20 mg/mL it is 12.5 units. Divide the milligrams in your vial by the millilitres of water you added to find which of those is yours.

Between 4.17 and 75.08 units, depending entirely on how concentrated your vial is — and that is something you decided when you chose your water volume. Enter your own vial below for the exact figure.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Calculator inputs

Convert from your concentration

Units only mean something after the vial and water volume are known.

Dose in mg

Tirzepatide in the vial (mg)

Bacteriostatic water added (mL)

At 10 mg/mL

2.5 mg = 25 units0.25 mL

On a U-100 syringe, where 100 units = 1 mL.

Why there is no single answer

A syringe unit measures volume, not mass: one unit is 1/100 of a millilitre. So Tirzepatide at 2.5 mg lands on a different mark at every concentration. Find the row matching the vial and water volume you actually used.

Concentration	Example vial + water	2.5 mg is
1 mg/mL	2 mg in 2 mL	250 units
2 mg/mL	4 mg in 2 mL	125 units
2.5 mg/mL	5 mg in 2 mL	100 units
5 mg/mL	10 mg in 2 mL	50 units
10 mg/mL	20 mg in 2 mL	25 units
20 mg/mL	40 mg in 2 mL	12.5 units

2.5 mg at every concentration

ISO 8537 fixes the U-100 scale, so 100 units is 1 mL on every insulin syringe sold for human use and the conversion is a division rather than a lookup. The divisor is your concentration. Each row below is a vial you might plausibly be holding rather than an abstract mg/mL figure, because nobody owns “12.5 mg/mL” — they own a 25 mg vial and a syringe of water.

Concentration	A vial that gives it	Draw	Units (U-100)	Reading it
3.33 mg/mL	10 mg vial + 3 mL	0.751 mL	75.08	Between the marks on every standard barrel
5 mg/mL	10 mg vial + 2 mL	0.5 mL	50	Printed mark on every U-100 barrel
6.67 mg/mL	20 mg vial + 3 mL	0.375 mL	37.48	Between the marks on every standard barrel
10 mg/mL	10 mg vial + 1 mL	0.25 mL	25	Printed on 0.3 and 0.5 mL barrels; between marks on a 1 mL
13.33 mg/mL	40 mg vial + 3 mL	0.188 mL	18.75	Between the marks on every standard barrel
15 mg/mL	30 mg vial + 2 mL	0.167 mL	16.67	Between the marks on every standard barrel
20 mg/mL	20 mg vial + 1 mL	0.125 mL	12.5	Half unit — needs a half-unit 0.3 mL barrel
30 mg/mL	30 mg vial + 1 mL	0.083 mL	8.33	Between the marks on every standard barrel
40 mg/mL	40 mg vial + 1 mL	0.063 mL	6.25	Between the marks on every standard barrel
60 mg/mL	60 mg vial + 1 mL	0.042 mL	4.17	Between the marks on every standard barrel

The dose is fixed across that table and the volume moves. Doubling the concentration halves the units — which is the practical reason to care about water volume at all: it is the only lever you have over how readable the mark is.

Does any approved label use 2.5 mg?

Yes — one approved schedule has a 2.5 mg step. The table places the figure on every one of those ladders, because the useful question is not only whether a label uses it but how far it is from one that does: a figure that lands on a step came from something checkable, one that falls between steps or above every maximum came from somewhere else.

Schedule	Starts at	Maximum	2.5 mg on this ladder
TirzepatideZepbound (weight management)	2.5 mg	15 mg	Labelled stepstarting dose, held at least 4 weeks
SemaglutideWegovy (weight management)	0.25 mg	7.2 mg	Between the 2.4 mg and 7.2 mg steps — not a dose on this label
LiraglutideSaxenda (weight management)	0.6 mg	3 mg	Between the 2.4 mg and 3 mg steps — not a dose on this label

A match is a statement about the number, not about you: each of those schedules also fixes a starting dose, a minimum interval between increases and a maximum, and a syringe enforces none of them. The step it matches is the one to read on the label, not the one to draw.

The water volume that puts 2.5 mg on a round mark

Most people meet this question the other way round: they know the dose, they own a vial, and they want the syringe to read something they can stop the plunger on. Water is the only lever. For each vial size Tirzepatide is sold in, this is the volume that lands 2.5 mg exactly on 10, 20, 25 or 50 units, and how many draws of 2.5 mg the vial physically holds.

Vial	Draws of 2.5 mg	10 units	20 units	25 units	50 units
10 mg	4	0.4 mL	0.8 mL	1 mL	2 mL
20 mg	8	0.8 mL	1.6 mL	2 mL	4 mLover a 3 mL vial
30 mg	12	1.2 mL	2.4 mL	3 mL	6 mLover a 3 mL vial
40 mg	16	1.6 mL	3.2 mLover a 3 mL vial	4 mLover a 3 mL vial	8 mLover a 3 mL vial
60 mg	24	2.4 mL	4.8 mLover a 3 mL vial	6 mLover a 3 mL vial	12 mLover a 3 mL vial

Greyed cells are volumes a standard vial will not hold or a syringe cannot measure. Between 20 and 50 units is where the published work on low-dose accuracy finds error smallest, so where two cells both fit, the one further right measures better. The draw count is arithmetic about a container — 24 draws of 2.5 mg from a 60 mg vial — and says nothing about whether 2.5 mg is anybody’s dose. That question belongs to the label and to whoever prescribed it, and the ladder table above tells you whether a label has an answer.

What the Tirzepatide label actually says

FDA-approvedHalf-life: About 5 days (5–6 days in obesity trials); steady state after 4 weeks of weekly dosing

Approved 13 May 2022 as Mounjaro for type 2 diabetes, and 8 November 2023 as Zepbound for chronic weight management; Zepbound added obstructive sleep apnea on 20 December 2024. Every approved presentation is a ready-to-use sterile solution — no FDA-approved tirzepatide product is a lyophilised powder requiring reconstitution. Powder vials come from compounders, and the FDA declared the tirzepatide shortage resolved on 19 December 2024, ending the shortage basis for compounding it.

That matters here because the approved schedule is a fixed ladder, and the conversion above does not know where on it you are. The dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose. The label is explicit that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. The maximum is 15 mg once weekly.

2.5 mg — starting dose, at least 4 weeks
5 mg — valid maintenance dose for weight reduction, at least 4 weeks
7.5 mg — titration step, at least 4 weeks
10 mg — maintenance; minimum maintenance dose for sleep apnea, at least 4 weeks
12.5 mg — titration step, at least 4 weeks
15 mg — maximum recommended dose

Full sourcing, the reconstitution calculator and the published evidence are on the Tirzepatide page.

Working it out yourself

Divide the milligrams of peptide in the vial by the millilitres of water you added. That is your concentration in mg/mL. Then divide 2.5 mg by that concentration to get the volume in millilitres, and multiply by 100 to turn millilitres into units on a U-100 syringe. Worked through at 10 mg/mL: 2.5 ÷ 10 = 0.25 mL, × 100 = 25 units. Two figures, one division, one multiplication. Every calculator doing this — including this one — is doing nothing more than that.

One honest caveat about the first step: the lyophilised cake occupies volume of its own, so the finished solution is marginally more than the water you added and the true concentration marginally lower than the division suggests. Measured displacement for lyophilised powders runs about 0.66 to 0.70 mL per gram of total solids, so a milligram-scale peptide vial displaces a few microlitres — well under one unit on a U-100 barrel, and finer than the barrel can be read. FDA labels state the nominal concentration without correcting for it either. The exception is a vial carrying a heavy bulking agent, where displacement can reach several percent.

For a fuller picture including the approved dosing schedule and its sources, see the Tirzepatide calculator.

Where this particular conversion goes wrong

The syringe is not U-100. A U-40 veterinary barrel is fixed at 40 units per mL by 21 CFR 522.1160 and is still sold for animal insulin, which is labelled at that strength. The 25 unit mark you want holds 0.25 mL on a U-100 barrel and 0.625 mL on a U-40 one. Two and a half times the volume, from a barrel that looks the same. Both over- and under-dosing from exactly this substitution are documented in the published case literature.
One mark either way. At 10 mg/mL this dose is 25 units. Stopping one printed mark early or late is a 4% error on a 0.3 or 0.5 mL barrel and a 8% error on a 1 mL barrel printed in 2-unit steps — the same slip, twice the consequence, because the coarser barrel moves twice the volume per mark.
Reading "2.5" as millilitres. 2.5 mg is 0.751 mL at the weakest concentration in the table and 0.042 mL at the strongest. The number never means millilitres on its own.
Assuming the vial holds what the label says. Every figure here starts from the milligrams stated on your vial. For an FDA-approved product that figure is verified; for a compounded or grey-market vial nobody has checked it, and no calculator can. The arithmetic is exact — its input may not be.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

FDA labelFDA / DailyMed· 2026-08
MOUNJARO (tirzepatide) injection — FDA prescribing information
FDA labelFDA / DailyMed· 2026-08
ZEPBOUND (tirzepatide) injection — FDA prescribing information
Published studyNew England Journal of Medicine· 2025
Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
GuidelineInternational Organization for Standardization· 2016-03
ISO 8537:2016 — Sterile single-use syringes, with or without needle, for insulin (scope and requirements; full text not public)
RegulatorFDA / Federal Register· 1998-05-13
Removal of Regulations Regarding Certification of Drugs Composed Wholly or Partly of Insulin — 63 FR 26694 (the repealed insulin colour scheme, and U-40 no longer marketed)
RegulatorUS Code of Federal Regulations / FDA
21 CFR 522.1160 — Insulin (animal drugs): 40 international units (IU) per millilitre
Published studyCase Reports in Endocrinology 2019;2019:7916435· 2019
Barrera F, Murvelashvili N. Poorly controlled type 3c diabetes due to use of veterinarian insulin syringes
Published studyDiabetology International 2024;15(3):544–549· 2024-05
Kondo M, Saji R, Yamada Y, et al. Analysis of factors affecting the accuracy of low-dose insulin dosage using syringes and vials
Published studyClinical Pediatrics 2004;43(1):69–74· 2004-01
Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump
Published studyBMJ Paediatrics Open· 2023
Zheng L-Y et al. Displacement volume of reconstituted powder injections and its effect on dosing accuracy